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Abstract
Objectives. To evaluate i) the correlation between vitamin D (vit. D) serum concentra-
tions and metabolic syndrome (MetS); ii) the efficacy of 6 months supplementation 
therapy with vit. D.
Method. 200 patients were enrolled. Blood analyses and anthropometric measurements 
were carried out. Patients with hypovitaminosis D received an oral supplement therapy.
Results. 81% of the sample shows vit. D levels < 30 ng/mL. Rate of MetS was significant-
ly higher in vit. D deficiency group than in vit D insufficiency (p = 0.009) and sufficiency 
(p = 0.002) groups. Vit. D shows a significant negative correlation with both waist circum-
ference (WC) (ρ - 0.202 p = 0.004) and glycaemia values (FBG) (ρ -0.185 p = 0.009). 
After the supplementation therapy in a group of 60 subjects a significant increase in vit. 
D levels (p = 0.001) and a significant reduction in WC values (p = 0.001) were observed.
Conclusions. MetS, WC and FBG appeared to be associated vit. D status and it is well-
known that central obesity, with the inflammatory alterations thereto correlated that 
determine insulin resistance, can be considered the “primum movens” for the develop-
ment of MetS.
 INTRODUCTION
Recent scientific developments confirm that vitamin 
D (vit. D) plays a relevant role in controlling osteoar-
ticular homeostasis, as well as in prevention and, in 
some cases, in treatment of pathologies affecting other 
organs and apparatuses, assuming its possible pleiotro-
pic action [1]. 
It is interesting to note a possible correlation between 
low vit. D levels and an increased cardiovascular risk 
that should therefore be investigated [2, 3]. Osteopo-
rosis and atherosclerosis are frequently diagnosed in 
geriatrics and a possible correlation between these con-
ditions was recently assumed [4]. Hypovitaminosis D, 
whose incidence increases with age, may represent an 
interesting risk factor common to the reduction of bone 
mass as well as of the atherosclerotic process [5]. More-
over, several scientific evidences support the hypothesis 
of a possible association between low vit. D levels and 
obesity, arterial hypertension, intolerance to glucose 
and dyslipidemia [3, 5-10]. Furthermore, a number of 
studies have investigated a possible correlation between 
hypovitaminosis D and metabolic syndrome (MetS), a 
condition characterized by the contemporary presence 
of central obesity, arterial hypertension and altered li-
pidic and glycide metabolism [11-13]. Nonetheless, 
results are often contradictory [14, 15]. Several stud-
ies showed that lower 25(OH)D concentrations are in-
dependently associated with an increased likelihood of 
MetS [11, 13, 16]. A recent publication has shown that 
in elderly patients a major serum level of vit. D is asso-
ciated to a lesser prevalence of MetS, dyslipidemia, ab-
domen obesity and hyperglycaemia [17]. Contrariwise, 
other authors failed to find an association of these fac-
tors [3, 14, 15]. These conflicting findings may be due 
to differences in the characteristics of the study popula-
tions, such as age, prevalence of cardio-metabolic risk 
factor, proportion of overweight or obese individuals, 
ethnicity and lifestyle. The different methods used for 
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determination of 25[OH)D may be a further source 
of confusion. Moreover, most of the results were not 
adjusted for medications and serum intact parathyroid 
hormone (PTHi). 
The primary aim of this study is to evaluate a possible 
correlation between 25-hydroxyvitamin D (25(OH)D) 
serum concentrations, the best biomarker of vitamin D 
status [18], and MetS in elderly subject, so far not over-
ly considered, as well as in middle-aged adult subjects 
in whom the presence of alterations typical of MetS is 
more common. 
The importance of keeping sufficient plasma levels of 
vit. D in order to implement primary prevention of falls 
and fractures is a matter of fact [19]. Furthermore, the 
possible role of vit. D supplementation therapy in con-
trolling the typical alterations of MetS has not yet been 
thoroughly analyzed. A recent meta-analysis showed 
that supplementation of vit. D is effective in prevent-
ing overall mortality in a long-term treatment [20]. A 
secondary aim of the study is to evaluate the efficacy of 
an oral supplementation therapy in subjects with hypo-
vitaminosis D evaluating its efficacy as regards reaching 
adequate serum vit. D levels as well as a possible control 
of the principal risk factors of MetS. 
MATERIALS AND METHODS
Community-dwelling subjects who visited the ambu-
latory of the Department of Cardiovascular, Respirato-
ry, Nephrological, Anesthesiological and Geriatric Sci-
ences of Sapienza University of Rome between March 
and June 2014, for evaluation of cardiovascular risk fac-
tors, were considered for this study. 
Exclusion criteria were: a long history of osteoporo-
sis; current treatment with vit. D, calcium supplements, 
other drugs for the treatment of osteoporosis/osteope-
nia; active gastroenteric pathology. 
The study was conducted according to the guidelines 
on biomedical research involving human subjects (Dec-
laration of Helsinki) and was approved by the ‘‘Science 
of Aging’’ Interdepartmental Research Center of Sapi-
enza University of Rome. Informed consent from each 
patient was obtained.
A clinical interview investigated medical history, 
home therapy and general habits of the patients. The 
anamnestic requirements for each patient were: osteo-
porosis in the family, cardiovascular illness, lifestyle (di-
etary survey or physical activity pattern, use of smoke 
and alcohol). 
Anthropometric measures were obtained: waist cir-
cumference (WC) was measured at the iliac crest with 
the patients standing; body mass index (BMI) was 
determined by dividing the weight (kilograms) by the 
square of height (meters).
For each patient was carried out a standard-12 devia-
tion ECG, a transthoracic echocardiogram and an Eco-
ColorDoppler to assess the presence of active cardiac 
pathologies; a liver ecography to assess the presence of 
liver insufficiency and steatosis was also performed.
Venous blood was withdrawn after an overnight fast. 
Standard laboratory techniques were adopted to assess 
high-density lipoprotein cholesterol (HDLc), triglycer-
ides (TG), fasting blood glucose (FBG) and serum uric 
acid (SUA). Fasting insulin and PTHi concentrations 
were determined by enzyme-linked immune-sorbant-
assay (ELISA) kit (third generation). 25(OH)D was 
assayed by using high-performance liquid chromatog-
raphy (HPLC) and expressed in nanograms/ milliliter 
(ng/ml).
The insulin-resistance (IR) was estimated by using 
Homeostasis Model Assessment Index of Insulin Re-
sistance (HOMA-IR). HOMA-IR was calculated with 
the following formula: [fasting insulin (U/ml) x fasting 
glucose (mmol/L) / 22.5] [21].
For the diagnosis of hypertension the clinical history 
and home therapy were considered. Blood pressure 
was measured twice to the right arm after a rest of 10 
minutes with subjects in sitting position, using a mer-
cury sphygmomanometer. Systolic (SBP) and diastolic 
(DBP) blood pressure levels were defined as first and 
fifth Korotkoff phases (mmHg). 
Diabetes mellitus was defined as self-reported diabe-
tes or by FBG ≥ 126 mg/dl.
MetS was diagnosed according to the National Cho-
lesterol Education Program Adult Treatment Panel III 
criteria (NCEP ATP III), 2001, by the presence of three 
or more of the following features: WC ≥ 88 cm; HDLc 
< 50 mg/dl; FBG > 110 mg/dl or anti-diabetic treat-
ment; fasting triglycerides ≥ 150 mg/dl; systolic blood 
pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 
85 mmHg or antihypertensive treatment [22].
Adherence to a healthy diet was assessed using the 
14-item Mediterranean diet assessment tool and obe-
sity indexes [23]. The questions therein analyzed the 
number of portions and the frequent use per product of 
the typical Mediterranean diet (Med diet) such as olive 
oil, fruit, wine, fish or the intake of foods not included 
in the traditional Med diet. The total score ranges from 
0 to 14: the higher the score, the higher the degree 
of adherence to the Med diet pattern. Each item was 
scored 0 or 1.
Physical activity habits were self-reported by patients 
with daily diaries. Diaries has been collected monthly. 
According to the Institute of Medicine (IOM) 2011 
criteria, vit. D status was categorized as follows: i) vit. 
D deficiency, defined by serum 25(OH)D less than 20 
ng/ml; ii) vit. D insufficiency, defined by serum 25(OH) 
of 20-29 ng/ml; iii) vit. D sufficiency, defined by serum 
25(OH)D ≥ 30 ng/ml [24].
Patients with hypovitaminosis D received an oral sup-
plement therapy (Cholecalciferol) [25]:
1. patients with 25(OH)D < 10 ng/ml received a loading 
dose of 50 000 IU once a week for 4 weeks, followed 
by a dose of 25 000 IU once a week for 4 weeks, fol-
lowed by a maintenance dose of 25 000 IU twice a 
month; 
2. patients with 10 < 25(OH)D < 20 ng/ml received a 
loading dose of 25 000 IU once a week for 4 weeks, 
followed by a maintenance dose of 25 000 IU twice 
a month;
3. patients with 20 < 25(OH)D < 30 ng/ml received a 
loading dose of 25 000 IU twice a month for 8 weeks, 
followed by a maintenance dose of 25 000 IU at 
month;
After 6 months the subjects were re-evaluated for the 
























single components of MetS, IR and vit. D status.
All statistical analysis were performed using the 
Statistical Package for the Social Science (SPSS) ver-
sion 22 for Windows. Data are presented as means ± 
standard deviations (sd) for continuous variables and 
as frequencies for discrete variables. One-way analysis 
of variance (ANOVA) was performed to investigate be-
tween groups differences in continuous variable while 
the Chi-square test (χ2) was used to explore between 
groups differences in discrete variable. Pearson’s corre-
lation test was used in order to investigate the relation-
ship between variables. The Student’s paired T test was 
used in order to compare variables’ baseline values with 
those post vit. D supplementation therapy.
A p value below 0.05 was deemed significant.
RESULTS
Two hundred patients were enrolled (mean age: 65 ± 
9.8; 45 males). 
By assessing serum levels of 25(OH)D, we found that 
81% of our study population had 25(OH)D < 30 ng/ml 
with a high prevalence of hypovitaminosis D in both 
sexes (83% in females vs 71% in males). In all, MetS 
was observed in 52.5%, hypertension in 65.5%, diabetes 
in 20.5%, nonalcoholic fatty liver in 59.5%. All diabetic 
subjects were on antidiabetic therapy. The style of life 
assessment showed poor adherence to the Med diet 
(88% of the sample achieved ≤ 7 points in the 14-item 
Med diet score, where 8, 9 o r ≥ 10 score indicates an 
high adherence to the Med diet) and to physical activity 
(only 15% of the sample reported to conduct a physical 
activity on a regular basis and /or 30 min brisk walk).
The relationship between vit. D levels and various 
conditions (hypertension, diabetes, nonalcoholic fatty 
liver, MetS and smoke) included in the present study 
was analyzed. Results showed a significant between 
groups difference only in MetS rate (χ2 = 13.66 p = 
0.001): the presence of MetS increased with the de-
crease of vit. D levels. More specifically the MetS rate 
in the group with vit. D deficiency was higher than the 
rate of the groups with both vit. D insufficiency and suf-
ficiency (respectively χ2 = 7.49 p = 0.009; χ2 = 10.32 
p = 0.002). 
As summarized in Table 1, data analysis showed 
a significant difference between groups in WC (p = 
0.02) and PTHi (p < 0.001) values. More specifically, 
WC values decreased with the increase of vit. D levels: 
post-hoc analysis with Bonferroni correction showed a 
significant difference in WC values only between the 
groups with deficiency and insufficiency in vit. D (p = 
0.04). Regarding PTHi variable, as expected, the values 
decreased with the increase of vit. D levels: post-hoc 
analysis with Bonferroni correction showed a significant 
difference in PTH values only between groups with de-
ficiency and insufficiency of vit. D (p = 0.03). A be-
tween groups difference tending to the significance (p = 
0.09) in both BMI and glycaemia values was observed. 
No further differences between groups were observed.
Analyzing the correlations between vit. D levels and 
the other variables included in the present study, a weak 
significant negative correlation was observed between 
vit. D levels and two components of MetS, respectively 
with both WC (ρ - 0.202 p = 0.004) and glycaemia val-
ues (ρ - 0.185 p = 0.009), while a negative correlation 
tending to the significance was noted with BMI levels 
(ρ - 0.135 p = 0.057). By controlling the correlation be-
tween vit. D levels and both WC, glycaemia and BMI 
values concurrently for the variables “gender” and “age” 
the significant negative correlation with WC and gly-
caemia values was confirmed (respectively ρ - 0.219; p 
= 0.002; ρ - 0.195 p = 0.005) and a significant negative 
correlation with the BMI values was found (ρ - 0.142 p 
= 0.04). 
As regard the efficacy of six months oral supplemen-
tation therapy with vit. D on some of the components 
of the MetS tested in a group of 60 subjects with hypo-
Table 1
Groups characteristics and differences in continuous variables




Vitamin D insufficiency 
group
20 < x < 30 ng/ml
(n = 53)





M sd M sd M sd
Age 65.2 10.7 64.85 8.3 62.97 9.5 0.737 n.s.
25(OH)D 12.3 4.4 24.5 2.6 43.2 15.2 247.8 0.001**
PTHi 59.23 29.7 48.8 24.3 45.8 21 4.79 0.001**
BMI 30.5 6 28.5 5.9 28.9 5.9 2.44 0.09
WC 102.7 15.5 97.6 15.4 95.6 13.7 3.92 0.02*
FBG 104.4 23.4 99 21.1 96.5 13.8 2.36 0.09
HOMA 2.9 2.25 2.8 4.5 2.3 1.7 0.616 n.s.
HDLc 56.7 17.6 59.9 16.2 55.8 14 0.882 n.s.
TG 133.9 74.7 115.8 78 122.3 50.6 1.23 n.s.
SUA 5.3 1.3 5.3 1.3 5.5 3.7 0.084 n.s.
* p < 0.05 ** p < 0 .01
25(OH)D = 25-hydroxyvitamin D; PTHi = intact parathyroid hormone; BMI = body mass index; WC = waist circumference; FBG = fasting blood glucose; HOMA =  
Homeostasis Model Assessment Index of Insulin Resistance; HDLc = high density lipoprotein cholesterol; TG = triglicerydes; SUA = serum uric acid.
























vitaminosis D the results showed a significant increase 
in vit. D average levels (p = 0.001) and a significant 
reduction in WC values (p = 0.001) (Table 2). 
DISCUSSION
Many studies highlight a widespread and ample dif-
fusion of hypovitaminosis D in the world population, 
regardless of the seasons and latitude [26, 27]. The re-
sults of our study confirm these data and it is useful 
to note that all subjects examined live in Rome, that is 
the second sunniest city in Europe (1687 hours of sun-
shine/year). Furthermore, among the subjects with low 
levels of vit. D, 62.2% showed an important deficit, that 
is with values of vitamins inferior to 20 ng/ml. Another 
interesting datum is the high prevalence of hypovita-
minosis D in both sexes. Therefore, as it is for women 
(whose controls are more widespread because of the 
major incidence of osteoporosis), also in males a proper 
dosage level of 25(OH)D3 is important. Furthermore, 
in a group substantially balanced between under/over 
65 years (45% vs 55%), it is interesting to note that the 
average age of the groups examined increased while the 
serum levels of vit. D lessened (Table 1). 
We found a significant association between vit. D 
status and MetS in line with previous reports [11, 13, 
16]. Moreover, a significant negative correlation was 
observed between vit. D levels and two components 
of MetS: WC and glycaemia values. As noted, central 
obesity can be considered one of the main causes of the 
MetS [28]. The visceral fat, in fact, correlates indepen-
dently with all MS components. The fatty tissue and 
the inflammatory alterations thereto correlated deter-
mine insulin resistance with reduced use of the mar-
ginal glucose and the alteration of the regulation and 
liver production of glucose. Visceral obesity and insulin 
resistance are furthermore associated with an increased 
production of adipokines, a molecule capable of caus-
ing ossidative stress, increase of inflammatory markers 
[tumor necrosis factors-α (TNF-α), C-reactive protein] 
and thrombosis as well as endothelial disfunction [29]. 
Normal serum vit. D may be associated with better en-
dothelial function and can exert an active role in adi-
pose tissue by inhibiting of chemokine and cytokine 
secretion in human adipocytes with benificial effects on 
cardiovascular health [30, 31]. 
We failed to find a correlation between vit. D status 
and serum lipid profile variables. Previous findings re-
ported conflicting results [16, 17, 32], but differences 
in the study populations should be considered, as well 
as the failure to adjust for potential confounding vari-
ables. Levels of serum pro-inflammatory cytokines, like 
TNF-α and interleukin 6, are negatively correlated with 
serum HDL-cholesterol levels and are also associated 
with hypertriglyceridemia [33, 34]. Low grade chronic 
inflammation has been widely confirmed to be associ-
ated with MetS and vit. D has been recognized to have 
anti-inflammatory properties [1]. Our results suffer 
from a lack of knowing the inflammatory status of the 
patients. 
Blood hypertension was not found to be associated 
with 25(OH)D. Pre-existing data are mixed [35-37] 
and confounded by differences in the study popula-
tions. Our results could be influenced by intra-groups 
differences (years since menopause for women, inflam-
matory status, different cardiovascular risk etc.). Future 
investigation on this topic are welcome.
The identification and treatment of hypovitamino-
sis D could be important not only in youth but also 
in elderly, in which MetS and in particular abdominal 
obesity are potential risk factors for disability [38]. 
It is apparent, therefore, the need to maintain suffi-
cient plasmatic levels of vit. D; however, there is no 
agreement on how to attain this objective [39, 40]. In 
this study, six months of vit. D supplementation in 60 
subjects has been proven to be efficacious in restoring 
normal levels of 25(OH)D3 in most of the patients, 
without side effects. Furthermore, after the supple-
mentation therapy, a significant reduction (p < 0.01) of 
the WC values was observed. It is common knowledge 
that overweight subjects with increased WC are ex-
posed to an higher risk of type 2 diabetes, hypertension 
and stroke [41]. In our samples we found a significant 
reduction of the WC after supplementation therapy 
which confirms an important role of the vit. D in the 
reduction of cardiovascular risk, also in consideration 
of the low adherence to the Med diet and to physi-
cal activity. In this respect, a recent study in young 
patients with BMI superior to 30 − regardless of the 
diet followed and of other possible variables which may 
interfere − has shown high concentrated levels of cal-
cium plus vit. D, correlated with a major body fat and 
visceral fat loss after three months [42]. Recently, nu-
Table 2
Effect of 6 months oral supplementation therapy in 60 subjects with  hypovitaminosis D
Variable Pre vitamin D oral 
supplementation therapy
Post vitamin D oral 
supplementation therapy
t p
M sd M sd
25(OH)D 15.3 6.9 33.3 14.9 -9.19 0.001*
WC 99.2 16.3 95.9 15.7 4.33 0.001*
FBG 100.3 22.8 97.1 16.7 1.01 n.s.
HDLc 56.5 16.4 58.4 15.8 -0.752 n.s.
TG 127.6 58.3 115.8 54.1 1.25 n.s.
*p < 0.01
25(OH)D  =  25-hydroxyvitamin D; WC =  waist circumference; FBG = fasting blood glucose; HDLc = high density lipoprotein cholesterol; TG = triglicerydes; SUA = 
serum uric acid.
























merous evidences have been provided that obesity can 
also be the consequence of an increased PTH levels 
and low vit. D status. Increased PTH levels enhances 
lipogenesis by an increased calcium influx into the adi-
pocytes [43]. Calcium and vit. D are important deter-
minants of PTH levels, and several studies have shown 
that the supplementation of these nutrients resulted 
also in weight loss [42-44]. 
Nevertheless the current study faces certain limita-
tions. Firstly, this study was based on a single measure-
ment of serum 25-(OH) vit. D as an indicator of vit. D 
status. Secondly, it is a cross-sectional study with small 
sample size. Thirdly, although the Authors adjusted for 
many potential confounders, residual confounding may 
remain (e.g. time spent outdoors, etc.).
Further studies with larger samples should be carried 
out to confirm the correlation between hypovitamino-
sis D and MetS, in order to evaluate the effects of a 
supplementation therapy on cardiovascular risk.
CONCLUSIONS
The results of our study demonstrate that:
• hypovitaminosis D is a condition quite common in 
both sexes; 
• there is a significant negative correlation between lev-
els of vit. D and MetS, along the lines demonstrated 
by other studies. Furthermore, vit. D levels are corre-
lated with two MetS components: glycaemia and WC; 
• after supplementation therapy in subjects with hy-
povitaminosis D a significant WC reduction was ob-
served, even with a low adherence to the healthy diet 
and to the physical activity;
• we believe it is indispensable to measure out the 
levels of vit. D − especially in subjects over 45 years 
old − and, when necessary, to provide an adequate 
supplementation therapy in order to aid the positive 
pleiotropic effects that this vitamin exerts also in re-
ducing cardiovascular risks. 
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